Myeloid sarcoma of the vulva post-bone marrow transplant presenting as isolated extramedullary relapse in a patient with acute myeloid leukemia  by Ahmed, Nazer et al.
case report
Hematol Oncol Stem Cell Ther 5(2)    Second Quarter 2012 hemoncstem.edmgr.com118
Allogeneic hematopoietic stem cell transplant (HSCT) is considered the most effective therapy to provide long term leukemia free 
survival in high-risk acute myeloid leukemia (AML). 
The therapeutic options for a relapsed AML are few 
and the underlying mechanism of immune escape for 
recurring relapse is not well understood.1 Isolated vul-
var myeloid sarcoma as an extramedullary relapse of 
leukemia is a very rare condition. Complete remission 
can be achieved with chemotherapy and there is  a lim-
ited role for surgical intervention. The following report 
is presented in view of its rarity and discussed in light of 
the available literature.
CaSE
A 41-year-old female with an unremarkable past medi-
cal history presented to the local hospital in March 
Myeloid sarcoma of the vulva post-bone 
marrow transplant presenting as isolated 
extramedullary relapse in a patient with acute 
myeloid leukemia
Nazer Ahmed,a Ismail Al-Badawi,a Wahiba Chebbo,a Naeem Chaudhri,b Ghada El-Goharyb
from the aDepartment of obstetrics and Gynecology, boncology Centre, King faisal specialist hospital and research Centre, riyadh, saudi 
arabia
Correspondence: naeem Chaudhri, mD ⋅ mBC 64, King faisal specialist hospital and research Centre, P.o. Box 3354, riyadh 11211, saudi 
arabia ⋅ t: +966-1-4647272 ⋅ chaudhri@kfshrc.edu.sa
hematol oncol ste Cell ther 2012; 5(2): 118-121
Doi: 10.5144/1658-3876.2012.118
myeloid sarcoma is a tumor of myoblasts or immature myeloid cells occurring in an extramedullary site. 
myeloid sarcoma of the female genital tract as an isolated initial presentation or isolated relapse is very 
rare as evidenced from a literature review. We report a case of vulvar myeloid sarcoma presenting as 
isolated relapse of acute myeloid leukemia (amL) after allogeneic hematopoietic stem cell transplant 
(hsCt). a 41-year-old female diagnosed with amL m5 achieved remission with chemotherapy and 
underwent allogeneic hsCt from an hLa-matched sibling donor. the post-transplant period was com-
plicated with chronic graft-versus-host disease. at 10 months post-transplant, she presented with a vulvar 
mass of six weeks duration. Excisional biopsy of the vulvar mass confirmed the diagnosis of myeloid sar-
coma as extramedullary relapse. Bone marrow biopsy was without evidence of leukemia. involvement 
of the vulva, vaginal and adjacent cervical area only was confirmed. she received re-induction chemo-
therapy with clinical regression of both the vulvar, vaginal and the cervical masses; this was followed by 
radiation therapy to an extramedullary site. the correct diagnosis of myeloid sarcoma, particularly of an 
isolated mass in the genital area, is important because of its rarity and the need for appropriate institution 
of therapy.
2010 complaining of easy fatigability and dizziness. A 
complete evaluation revealed an initial WBC count of 
120×109/L with myeloid blasts and a bone marrow 
examination consistent with acute myeloid leukemia 
(AML M5) and normal cytogenetics. She received in-
duction chemotherapy with idarubicin 12 mg/m2×3 
days, cytarabine 100 mg/m2 continuous infusion for 7 
days and etoposide 100 mg/m2×5 days (ICE). Day 14 
bone marrow examination revealed refractory leukemia. 
She received salvage chemotherapy consisting of the 
mitoxantrone, etoposide and cytarabine (MEC) proto-
col. On day 28 of salvage chemotherapy, she achieved 
complete hematological remission with no evidence of 
bone marrow infiltration of leukemic cells. The patient 
was referred to our hospital for allogeneic HSCT from 
an HLA-matched sister. She underwent allogeneic pe-
ripheral blood HSCT in August 2010 with a myeloab-
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lative conditioning regimen of busulfan and cyclophos-
phamide (BU-CY2). The post-transplant period was 
complicated by development of chronic GVHD with 
involvement of skin, oral mucosa, eyes and weight loss. 
She was treated with cyclosporine and prednisone with 
a fairly good response. On regular follow up in May 
2011, she presented with a right vulvar mass lesion of 
6-weeks duration. There was no abnormal vaginal bleed-
ing or pelvic pain. She was referred to the gynecological 
clinic for further evaluation. On examination, there was 
2×2 cm tender mass on the right vulva and the initial 
impression was Bartholine cyst. She underwent ex-
amination under anesthesia and vulvar mass excisional 
biopsy. After complete dissection of the mass from ad-
jacent vulvar tissue, a gray mass measuring 2×1.5×1.5 
cm was sent for histopathology. The result confirmed 
myeloid sarcoma. Further evaluation with MRI pelvis 
showed intermediate signal intensity soft tissue mass 
circumferentially surrounding the cervix and vagina as 
well as urethra with intact fibrous stromal tissue. This 
soft tissue mass was invading the parametrium with 
involvement of the labia minora. Bone marrow biopsy 
showed no evidence of leukemia at this time. The di-
agnosis of relapse of isolated extramedullary leukemia 
was made. She underwent re-induction chemotherapy 
with an intermediate dose of cytarabine 1.5 g/m2 every 
12 hours for 6 doses, followed by radiation therapy to 
the area of the cervical, vaginal and vulvar mass for a 
total dose of 2000 CGy. CT scan repeated one month 
after treatment showed complete resolution of the vul-
var, vaginal and cervical mass. She remained in complete 
remission on follow up.
In February 2012, the patient was admitted to the 
hospital for evaluation of a right breast mass accompa-
nied with persistent headache. Ultrasound of the breast 
showed a small breast mass at 10 o’clock. Biopsy was 
consistent with myeloid sarcoma. The bone marrow 
showed no evidence of leukemia. The result of the CSF 
examination confirmed CNS leukemia. For the CNS 
involvement, she received intrathecal chemotherapy and 
12 fractions of cranial radiation therapy up to the C2 
level for a total dose of 2400 CGy. Radiation therapy 
was also given for the breast mass for a total of 2400 
CGy. The overall management at this stage of extensive 
multiple site extramedullary relapse was palliation and 
comfort care. 
DISCuSSIOn
Extramedullary relapse after HSCT for AML is a rare 
event and is less well defined than systemic, hematolog-
ic relapse. Myeloid sarcoma involving the gynecologic 
tract, prompting surgical biopsy or excision, is uncom-
mon. As described in the literature, most patients also 
have evidence of AML or a myelodysplastic or myelo-
proliferative neoplasm diagnosed in the past or virtually 
simultaneously with the diagnosis of myeloid sarcoma.
Histologically, the diagnosis of myeloid sarcoma 
can be challenging to surgical pathologists when the 
neoplasm is found in an unusual location, particularly 
when the neoplastic cells are immature or when myeloid 
sarcoma occurs in the absence of any other evidence of 
AML. The rate of misdiagnosis (including incomplete 
and incorrect diagnoses) for cases of myeloid sarcoma 
reported in the literature is appreciable, although it is 
much lower in the era of immunohistochemical analy-
sis. In our case, immunohistochemical staining and im-
munophenotypic analysis confirmed extramedullary 
leukemia (myeloid sarcoma) (Table 1). 
In our review of the literature, we found 50 cases 
of myeloid sarcoma of the gynecologic tract reported 
with a history of AML and only two cases where the 
vulva was primarily involved. The first one was reported 
by Erşahin et al2 of a 73-year-old patient with a previ-
ous history of AML. Isonishi et al3 reported a case of 
a 21-year-old female with isolated vulvar myeloid sar-
coma. She was treated with chemotherapy and bone 
marrow transplant, but she developed acute myeloid 
leukemia after complete remission.
 Twenty-eight patients with isolated myeloid sarco-
ma of the female genital tract are reported in the litera-
ture and they were treated with different management 
protocols. Complete remission and a report of a 10-year 
remission were achieved with chemotherapy (Table 2)4 
and none of the patients were treated with hysterecto-
my or salpingo-oophorectomy.
Allogeneic HSCT is considered a curative treatment 
for various malignant hematological disorders includ-
ing AML. One of the major causes of mortality after 
allogeneic HSCT is relapse of the disease. Several fac-
tors affect the outcome, including disease status at the 
time of transplant, histology, chemotherapy sensitivity, 
type of allograft and conditioning regimen. Treatment 
of relapsed disease is also affected by different factors 
including disease status at the time of relapse. The 
treatment mainstay is donor lymphocyte infusion, but 
Table 1. immunophenotypic analysis. 
mpO positive Cd10 negative
Cd43 positive Cd3 negative
Cd117 positive Cd20 negative
S100 negative Cd68 negative
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Table 2. Summary of published reports of myeloid sarcoma of the female genital tract.
Report Organ involved Age (y) AML Previous AML Concurrent Treatment Outcome
Berard et al Uterine cervix 39 no not stated radiation died, 5 mo
Seo et al Uterine cervix 65 no no radiation recurrence, 26 mo; died, 34 mo
abeler et al Uterine cervix 59 no no radiation aml, 3 mo; died, 4 mo
Harris and 
Scully Uterine cervix 71 no no Chemotherapy aml, 12 mo
Kao et al Uterine cervix 34 no no Chemotherapy died, 17 mo
Banik et al Uterine cervix 32 no no radiation and chemotherapy anel, 11 mo
reynaud et al Uterine cervix 48 no no Chemotherapy died, 24 mo
Hernandez et al Uterine cervix 48 no no Chemotherapy and  BmT
aml-m2, 8 mo; 
died, 10 mo
Garcia et al Uterine cervix 37 no no Chemotherapy anel, 2 mo
Garcia et al Uterine cervix 34 no no Chemotherapy anel, 12.5 y
Spahr et al Uterine corpus 39 no no no died, 6 d
Schafer et al Ovary 28 no no not stated aml, 3 mo
pressler et al Ovary 49 no no not stated anel, 12 mo
aguiar et al Ovary 31 no no Chemotherapy aml-m2, 12 mo; died, 14 mo
Oliva et al Ovary 30 no not stated not stated died, 24 mo
Oliva et al Ovary 31 no not stated Chemotherapy not stated
Oliva et al Ovary 31 no not stated not stated not stated
Oliva et al Ovary 43 no no Chemotherapy anel, 18 mo
Jung et al Ovary 12 no no not stated anel, 7 mo
Sreejith et al Ovary 26 no no Chemotherapy anel, 12 mo
Garcia et al Ovary 25 no no Chemotherapy
recurrence, 
24 mo; anel, 
30 mo
Oliva et al Vagina 73 no no radiation recurrence, 30 mo; died, 31 mo
Hernandez et al Vagina 48 no no Chemotherapy and BmT
aml-m5a, 4 
mo; died, 10 mo
Harris and 
Scully ≥2 Gyne sites 48 no no
radiation and 
chemotherapy aml, 2 mo
Garcia et al Gynecologic sites 59 no no Chemotherapy died, 2 mo
Garcia et al ≥2 Gynecologic sites 17 no no radiation
aml, 2 mo; 
died, 5 mo
isonishi et al Vulva 21 no no Chemotherapy and BmT not stated
aml: acute myeloid leukemia; anel: alive with no evidence of leukemia; BmT: Bone marrow transplantation. am J Clin pathol 2006;125:783-790
case reportmYelOid SarCOma OF THe VUlVa
Hematol Oncol Stem Cell Ther 5(2)     Second Quarter 2012 hemoncstem.edmgr.com 121
also includes chemotherapy and second alloHSCT.5 A 
recent study examined the incidence and risk factors for 
extramedullary (EM) and bone marrow (BM) relapse. 
Genitourinary EM relapse was rare. The time-to-relapse 
in the EM sites was longer and patients were more likely 
to have had chronic GVHD. The survival after EM re-
lapse was reported to be better and improved outcome 
with systemic therapy.6 Our patient presented with EM 
relapse 10 months after allogeneic HSCT and had chron-
ic GVHD for 6 months. She responded to the combined 
therapy and remained alive on recent follow up.
We have recently described a pattern of relapse in 601 
patients who received an allogeneic HSCT at our insti-
tution for acute or chronic leukemia and myelodysplasia 
over a period of 18 years. We showed a correlation be-
tween chronic GVHD and extramedullary relapse, sug-
gesting that the expected graft-versus-leukemia effect in 
patients with chronic GVHD may preferentially main-
tain marrow remission without preventing relapse in ex-
tramedullary sites.7
In conclusion, the diagnosis and the management of 
myeloid sarcoma of the female genital tract, because of 
its rarity, is challenging for both the anatomic patholo-
gist and the oncologist. In a subset of patients, systemic 
therapy can induce complete remission and long-term 
survival. Development of GVHD has an effect on the 
occurrence and outcome of relapse. There seems to be a 
better protection for the BM site than in patients who did 
not develop GVHD. The outcome for overall survival is 
better in EM relapse with combined therapy as compared 
to BM relapse.
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